Methods of using inhibitors of sodium-glucose cotransporters 1 and 2

A dose of 300 mg/day or less (e.g., 250, 200, 150, 100, or 50 mg/day or less) of a dual SGLT1/2 inhibitor of the formula:

• or a pharmaceutically acceptable salt thereof, for use in improving the cardiovascular or metabolic health of a diabetic or pre-diabetic patient, wherein:
• each R1A is independently hydrogen, alkyl, aryl or heterocycle;
• each R6 is independently hydrogen, hydroxyl, amino, alkyl, aryl, cyano, halogen, heteroalkyl, heterocycle, nitro, C≡CR6A, OR6A, SR6A, SOR6A, SO2R6A, C(O)R6A, CO2R6A, CO2H, CON(R6A)(R6A), CONH(R6A), CONH2, NHC(O)R6A, or NHSO2R6A;
• each R6A is independently alkyl, aryl or heterocycle;
• each R7 is independently hydrogen, hydroxyl, amino, alkyl, aryl, cyano, halogen, heteroalkyl, heterocycle, nitro, C≡CR7A, OR7A, SR7A, SOR7A, SO2R7A, C(O)R7A, CO2R7A, CO2H, CON(R7A)(R7A), CONH(R7A), CONH2, NHC(O)R7A, or NHSO2R7A;
• each R7A is independently alkyl, aryl or heterocycle;
• m is 1-4;
• n is 1-3;
• p is 0-2;
• and
• wherein each alkyl, aryl, heteroalkyl or heterocycle is optionally substituted with one or more of alkoxy, amino, cyano, halo, hydroxyl, or nitro.